Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

COVID-19 'war games': the computer program that could help save your job

11/11/2020 | 09:19am EST
FILE PHOTO: A woman uses a computer keyboard in this photo illustration

LONDON (Reuters) - Bank of England Chief Economist Andy Haldane has signed up to judge the winner of a 'war game' designed to help firms find alternatives to mass layoffs in the face of a coronavirus-driven slowdown.

Confronted with the most unpredictable pandemic in memory, cost-conscious firms have already axed millions of staff worldwide, while UK redundancies hit a record high of 314,000 in the quarter to Sept. 30, official data showed on Tuesday.

Unilever-owned tech firm uFlexReward created the COVID-19 War Game to allow executives to explore the impact of huge job cuts on their future earnings prospects.

"Many companies across the UK are facing financial strains as a result of the COVID crisis," Haldane told Reuters.

"Simulation tools can help us understand how best to alleviate these strains while preserving jobs, in a way that helps both businesses when making difficult commercial decisions and policymakers when making difficult economic decisions."

The game, designed during Britain's first lockdown this year and available free to play on the uFlexReward website, calls on players to devise a strategy to cut people costs of a fictional firm by 20%.

Participants weigh up the pros and cons of large-scale redundancies versus alternatives, for the long-term benefit of the firm as well as the broader economy.

It collates staff salaries, pensions, bonuses and share awards into one real-time cost-base, helping players see different ways of trimming overheads more clearly.

This can include making lots of smaller cost cuts in a so-called 'broad-front' approach, rather than one large saving in more focused cuts like scrapping entire business units or the staff bonus pool.

Financial firms have historically slashed highly paid workforces on the eve of recession, only to rehire rapidly when the economy rebounds.

Swapping this convention for a broad-front approach could minimise the risks that employers end up understaffed and under-skilled when the recovery kicks off, uFlexReward Chief Executive Ken Charman said.


Employers in multiple sectors are facing the prospect of a broader revolution in the world of work, triggered by technology and mass remote working.

"We are still stuck in a very Victorian view of what work is - with fixed working days, for a single employer and in a typically narrow role," Charman said.

"But change is coming that will allow people to be several things at once ... if companies lose people who are highly trained, experienced and loyal, they won't get them back," he said.

Charman hopes the game might persuade employers to waive or cut dividends as well as executive pay increases, and offer job-sharing, reduced hours or part-time roles with flexibility to work elsewhere to staff who might otherwise end up unemployed.

Pushing through alternatives to mass layoffs will require strong leadership and communication, particularly when thousands of employee contracts need to be renegotiated, but retaining staff could leave firms better placed when the recovery begins, Charman said.

"Executives need to be willing to abandon the old conventions; there will be resistance and they've got to be able to convince people this is in their best interests," he said.

"Employers, big companies and big financial institutions are part of our critical national infrastructure as much as the National Grid. They are the engines of our growth, but they are under threat."

Judging of the head-to-head version of the game, featuring teams made up of executives from Unilever and NYSE-listed technology services provider Endava, will take place on Dec. 3.

Together with Haldane, AstraZeneca senior vice president of reward and inclusion Rebekah Martin, Unilever head of global reward Constantina Tribou, and author David Goodhart are among those judging the strategies.

(Reporting by Sinead Cruise; Editing by Jan Harvey)

By Sinead Cruise

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.50% 7632 Delayed Quote.3.66%
ENDAVA PLC -0.01% 78.41 Delayed Quote.2.16%
J SAINSBURY PLC -0.46% 237.1 Delayed Quote.5.54%
LLOYDS BANKING GROUP PLC 0.88% 36.2579 Delayed Quote.-1.39%
NATIONAL GRID PLC -0.59% 870.6 Delayed Quote.1.20%
PROS HOLDINGS, INC. -4.37% 45.3 Delayed Quote.-10.77%
UNILEVER N.V. 0.69% 49.355 End-of-day quote.-0.80%
All news about ASTRAZENECA PLC
03:42aSouth Africa is promised 9 million J&J vaccine shots - Business Day
02:24aASTRAZENECA : Brazil inoculates first citizens against COVID-19; grants 2 vaccin..
02:17aAstraZeneca's Enhertu Treatment for Metastatic Gastric Cancer Gains Approval ..
01/17ASTRAZENECA : COVID-19 Vaccine Gains Emergency Use Approval in Pakistan
01/17ASTRAZENECA : COVID-19 Vaccine Gets Emergency Use Approval in Brazil
01/17ASTRAZENECA : Brazil Starts Its Covid-19 Vaccine Rollout -- 4th Update
01/17ASTRAZENECA : Brazil's health agency approves the use of two vaccines
01/17ASTRAZENECA : Brazil Starts Its Covid-19 Vaccine Rollout -- 3rd Update
01/17ASTRAZENECA : Brazil Authorizes Use of Two Covid-19 Vaccines -- Update
01/17Brazil Authorizes Use of Two Covid-19 Vaccines
More news
Financials (USD)
Sales 2020 26 400 M - -
Net income 2020 2 992 M - -
Net Debt 2020 13 217 M - -
P/E ratio 2020 43,0x
Yield 2020 2,73%
Capitalization 135 B 135 B -
EV / Sales 2020 5,63x
EV / Sales 2021 4,89x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 126,21 $
Last Close Price 103,14 $
Spread / Highest target 51,3%
Spread / Average Target 22,4%
Spread / Lowest Target -18,5%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.86%421 997
ROCHE HOLDING AG2.48%305 385
NOVARTIS AG1.97%218 041
MERCK & CO., INC.1.93%210 954
PFIZER INC.-0.30%203 993